Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low/intermediate‐1–risk myelodysplastic syndrome and thrombocytopenia
Pharmacology, Toxicology and Pharmaceutical Science
4
4%
Agricultural and Biological Sciences
3
3%
Biochemistry, Genetics and Molecular Biology
2
2%
Mathematics
1
1%
Other
5
5%
Unknown
33
36%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 March 2025.
All research outputs
#3,035,188
of 34,526,284 outputs
Outputs from Cancer (0008543X)
#2,714
of 19,194 outputs
Outputs of similar age
#25,874
of 270,685 outputs
Outputs of similar age from Cancer (0008543X)
#32
of 139 outputs
Altmetric has tracked 34,526,284 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 19,194 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.3. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 270,685 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 139 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.
